Miguel A Pappolla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/783487/publications.pdf

Version: 2024-02-01

78 papers 8,101 citations

66234 42 h-index 71532 76 g-index

80 all docs

80 docs citations

80 times ranked 7941 citing authors

#	Article	IF	Citations
1	Tryptophan in Nutrition and Health. International Journal of Molecular Sciences, 2022, 23, 5455.	1.8	5
2	HIV-Related Neuropathy: Pathophysiology, Treatment and Challenges. Journal of Neurology and Experimental Neuroscience, 2021, 7, 15-24.	0.2	2
3	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiology of Disease, 2021, 156, 105403.	2.1	39
4	Methodology for Evidence Synthesis and Development of Comprehensive Evidence-Based Guidelines for Interventional Techniques in Chronic Spinal Pain. Pain Physician, 2021, 24, S1-S26.	0.3	4
5	Insulin Resistance is Associated with Central Pain in Patients with Fibromyalgia. Pain Physician, 2021, 24, 175-184.	0.3	2
6	Is insulin resistance the cause of fibromyalgia? A preliminary report. PLoS ONE, 2019, 14, e0216079.	1.1	6
7	Do Regenerative Medicine Therapies Provide Long-Term Relief in Chronic Low Back Pain: A Systematic Review and Metaanalysis. Pain Physician, 2018, 21, 515-540.	0.3	39
8	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease. Current Alzheimer Research, 2015, 12, 32-46.	0.7	255
9	Evidence for lymphatic $\hat{A^2}$ clearance in Alzheimer's transgenic mice. Neurobiology of Disease, 2014, 71, 215-219.	2.1	48
10	Evidence of a Novel Mechanism for Partial \hat{I}^3 -Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid \hat{I}^2 Protein. PLoS ONE, 2014, 9, e91531.	1.1	19
11	Major Carboxyl Terminal Fragments Generated by \hat{I}^3 -Secretase Processing of the Alzheimer Amyloid Precursor Are 50 and 51 Amino Acids Long. American Journal of Geriatric Psychiatry, 2013, 21, 474-483.	0.6	12
12	Targets for AD treatment: conflicting messages from \hat{I}^3 -secretase inhibitors. Journal of Neurochemistry, 2011, 117, 359-374.	2.1	59
13	Differential Accumulation of Secreted AβPP Metabolites in Ocular Fluids1. Journal of Alzheimer's Disease, 2010, 20, 1243-1253.	1.2	52
14	Leptin and the skin: a new frontier. Experimental Dermatology, 2010, 19, 12-18.	1.4	82
15	Amphiphilic Amide Nitrones: A New Class of Protective Agents Acting as Modifiers of Mitochondrial Metabolism. Journal of Medicinal Chemistry, 2010, 53, 4849-4861.	2.9	21
16	Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia. American Journal of Medicine, 2010, 123, 267-274.	0.6	102
17	A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan. PLoS ONE, 2010, 5, e10206.	1.1	38
18	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	1.5	65

#	Article	IF	Citations
19	Frontiers in the pathogenesis of Alzheimer's disease. Indian Journal of Psychiatry, 2009, 51 Suppl 1, S56-60.	0.4	3
20	Beta-Secretase: Structure, Function, and Evolution. CNS and Neurological Disorders - Drug Targets, 2008, 7, 278-294.	0.8	93
21	Value in Development of a TAPIR-Like Mouse Monoclonal Antibody to $\hat{Al^2}$. Journal of Alzheimer's Disease, 2008, 14, 175-177.	1.2	3
22	Fine-Tuning the Amphiphilicity:  A Crucial Parameter in the Design of Potent α-Phenyl- <i>N</i> - <i>tert</i> -butylnitrone Analogues. Journal of Medicinal Chemistry, 2007, 50, 3976-3979.	2.9	19
23	A unique case of limb-girdle muscular dystrophy type 2A carrying novel compound heterozygous mutations in the human CAPN3 gene. European Journal of Neurology, 2007, 14, 819-822.	1.7	5
24	Insulysin Cleaves the APP Cytoplasmic Fragment at Multiple Sites. Neurochemical Research, 2007, 32, 2225-2234.	1.6	21
25	Fluorinated Amphiphilic Amino Acid Derivatives as Antioxidant Carriers:  A New Class of Protective Agents. Journal of Medicinal Chemistry, 2006, 49, 2812-2820.	2.9	44
26	Luteinizing hormone modulates cognition and amyloid- \hat{l}^2 deposition in Alzheimer APP transgenic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 447-452.	1.8	165
27	Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid \hat{l}^2 peptide levels. Neurobiology of Disease, 2006, 22, 651-656.	2.1	108
28	Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH1 acting as a highly potent antioxidant agent. Journal of Neurochemistry, 2005, 95, 962-973.	2.1	41
29	Alzheimer's Disease—A Dysfunction in Cholesterol and Lipid Metabolism. Cellular and Molecular Neurobiology, 2005, 25, 475-483.	1.7	43
30	Melatonin Relieves the Neural Oxidative Burden that Contributes to Dementias. Annals of the New York Academy of Sciences, 2004, 1035, 179-196.	1.8	75
31	Î ² -Secretase Processing of the Alzheimer's Amyloid Protein Precursor (APP). Journal of Molecular Neuroscience, 2003, 20, 233-240.	1.1	81
32	Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. Journal of Molecular Neuroscience, 2003, 20, 395-406.	1.1	47
33	Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magnetic Resonance in Medicine, 2003, 50, 293-302.	1.9	267
34	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 1101-1108.	2.1	295
35	Cholesterol, \hat{l}^2 -amyloid, and Alzheimer's disease. Advances in Cell Aging and Gerontology, 2003, 12, 163-175.	0.1	0
36	Deficiency of chaperonin 60 in Down's syndrome. Journal of Alzheimer's Disease, 2002, 4, 479-486.	1.2	14

#	Article	IF	CITATIONS
37	Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis1 1This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease.―The full list of papers may be found on the homepage of the journal Free Radical Biology and Medicine, 2002, 33, 173-181.	1.3	70
38	Statin therapy for Alzheimer's disease. Journal of Molecular Neuroscience, 2002, 19, 155-161.	1.1	152
39	Development of indole-3-propionic acid (OXIGON™) for alzheimer's disease. Journal of Molecular Neuroscience, 2002, 19, 213-217.	1.1	136
40	The neuroprotective activities of melatonin against the Alzheimer \hat{l}^2 -protein are not mediated by melatonin membrane receptors. Journal of Pineal Research, 2002, 32, 135-142.	3.4	83
41	Melatonin Reverses the Profibrillogenic Activity of Apolipoprotein E4 on the Alzheimer Amyloid Aβ Peptideâ€. Biochemistry, 2001, 40, 14995-15001.	1.2	147
42	A Cholesterol-Lowering Drug Reduces \hat{l}^2 -Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Neurobiology of Disease, 2001, 8, 890-899.	2.1	505
43	α-spectrins are major ubiquitinated proteins in rat hippocampal neurons and components of ubiquitinated inclusions in neurodegenerative disorders. Brain Research Bulletin, 2001, 54, 405-411.	1.4	13
44	Induction of NADPH cytochrome P450 reductase by the Alzheimer β-protein. Amyloid as a †foreign body'. Journal of Neurochemistry, 2001, 78, 121-128.	2.1	17
45	Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain. Free Radical Biology and Medicine, 2001, 31, 315-320.	1.3	22
46	Amyloid Deposition in Diffuse Plaques May Or May Not Start at the Neuronal Cell Surface Membrane. Journal of Neuropathology and Experimental Neurology, 2001, 60, 105.1-105.	0.9	1
47	An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. Journal of Neural Transmission, 2000, 107, 203-231.	1.4	229
48	Oxidative Stress and the Amyloid Conundrum. What is the Connection?. Journal of Alzheimer's Disease, 2000, 2, 79-82.	1.2	3
49	Neuronal Oxidative Stress Precedes Amyloid-β Deposition in Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2000, 59, 1011-1017.	0.9	307
50	Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model. Neurobiology of Disease, 2000, 7, 321-331.	2.1	964
51	RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer's Disease. Journal of Neuroscience, 1999, 19, 1959-1964.	1.7	708
52	Potent Neuroprotective Properties against the Alzheimer \hat{I}^2 -Amyloid by an Endogenous Melatonin-related Indole Structure, Indole-3-propionic Acid. Journal of Biological Chemistry, 1999, 274, 21937-21942.	1.6	317
53	Indole-3-propionate: a potent hydroxyl radical scavenger in rat brain. Brain Research, 1999, 815, 382-388.	1.1	84
54	Increased Expression but Reduced Activity of Antioxidant Enzymes in Alzheimer's Disease. Journal of Alzheimer's Disease, 1999, 1, 139-145.	1.2	134

#	Article	IF	Citations
55	Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis. Acta Neuropathologica, 1998, 95, 297-301.	3.9	23
56	Inhibition of Alzheimer \hat{l}^2 -Fibrillogenesis by Melatonin. Journal of Biological Chemistry, 1998, 273, 7185-7188.	1.6	309
57	Amyloidâ€Î² Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. Journal of Neurochemistry, 1998, 70, 2212-2215.	2.1	499
58	The Amyloid \hat{l}^2 Protein Induces Oxidative Damage of Mitochondrial DNA. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1356-1362.	0.9	94
59	Prophylactic Actions of Melatonin in Oxidative Neurotoxicity. Annals of the New York Academy of Sciences, 1997, 825, 70-78.	1.8	78
60	Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide. Journal of Neuroscience, 1997, 17, 1683-1690.	1.7	324
61	Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis. Autoimmunity, 1996, 24, 157-165.	1.2	22
62	The heat shock/oxidative stress connection. Molecular and Chemical Neuropathology, 1996, 28, 21-34.	1.0	31
63	Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization. Journal of Neuroscience Research, 1995, 40, 694-706.	1.3	60
64	Reinduction of Experimental Autoimmune Encephalomyelitis in Mice. Cellular Immunology, 1995, 162, 235-240.	1.4	17
65	Heat-shock induces abnormalities in the cellular distribution of amyloid precursor protein (APP) and APP fusion proteins. Neuroscience Letters, 1995, 192, 105-108.	1.0	10
66	Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1995, 58, 61-69.	1.1	42
67	Complement depletion affects demyelination and inflammation in experimental allergic neuritis. Journal of Neuroimmunology, 1995, 58, 157-165.	1.1	48
68	Oxygen-free radicals and amyloidosis in alzheimer's disease: Is there a connection?. Neurobiology of Aging, 1994, 15, 457-459.	1.5	10
69	Oxygen free radicals as inducers of heat shock protein synthesis in cultured human neuroblastoma cells: Relevance to neurodegenerative disease. European Archives of Psychiatry and Clinical Neuroscience, 1993, 242, 262-267.	1.8	71
70	The Alzheimer's Amyloid Precursor Is Cleaved Intracellularly in the Trans-Golgi Network or in a Post-Golgi Compartment. Annals of the New York Academy of Sciences, 1992, 674, 118-128.	1.8	26
71	Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells. Journal of Neuroscience Research, 1992, 33, 319-329.	1.3	149
72	Aging of the neuroendocrine system: Impaired neuropeptide control of thyroid stimulating hormone. Age, 1990, 13, 37-38.	3.0	0

#	Article	IF	CITATIONS
73	Ultrastructural evidence that insoluble microtubules are components of the neurofibrillary tangle. European Archives of Psychiatry and Neurological Sciences, 1990, 239, 314-319.	0.9	12
74	Bradykinin induces superoxide anion release from human endothelial cells. Journal of Cellular Physiology, 1990, 143, 21-25.	2.0	132
75	Permanent Alterations in the Hypothalamic-Pituitary-Thyroid Axis in the Rat Following Phenytoin Exposure In Utero. Hormone and Metabolic Research, 1990, 22, 521-523.	0.7	1
76	Heat Shock Protein Response in Alcoholic Liver Disease. Laboratory Medicine, 1990, 21, 811-814.	0.8	2
77	Carbon disulfide axonopathy. Another experimental model characterized by acceleration of neurofilament transport and distinct changes of axonal size. Brain Research, 1987, 424, 272-280.	1.1	45
78	Serum protein leakage in aged human brain and inhibition of ligand binding at alpha2- adrenergic and cholinergic binding sites. Synapse, 1987, 1, 82-89.	0.6	22